COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Tiotropium Bromide Alone vs Tiotropium Bromide and Formoterol Fumarate in Subjects With COPD (Study P04272)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00139932
Recruitment Status : Completed
First Posted : August 31, 2005
Last Update Posted : March 24, 2017
Integrated Therapeutics Group
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.

Brief Summary:
This study is being conducted to determine if the co-administration of formoterol fumarate and tiotropium bromide is more effective than the use of tiotropium bromide alone in patients with COPD.

Condition or disease Intervention/treatment Phase
Pulmonary Disease, Chronic Obstructive Drug: formoterol fumarate Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 255 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Double-Blind Randomized, Parallel-Group, Multicenter Clinical Study to Compare the Efficacy and Tolerability of Tiotropium Bromide Alone vs. the Co-Administration of Tiotropium Bromide and Formoterol Fumarate in Subjects With COPD
Actual Study Start Date : September 1, 2005
Actual Primary Completion Date : November 21, 2006
Actual Study Completion Date : November 21, 2006

Resource links provided by the National Library of Medicine

Primary Outcome Measures :
  1. effects of tiotropium bromide alone vs.the effect of tiotropium bromide and formoterol fumarate [ Time Frame: 12 weeks ]
    To compare the effects of tiotropium bromide alone vs. the effects of co-administration of tiotropium bromide and formoterol fumarate on the change from baseline of the normalized area under the time curve (AUC) for FEV1 for the 0 hour to 4 hours post-morning dose at the last study visit.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   40 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subjects must have a clinical history of COPD.
  • Subjects must be current cigarette smokers or ex-smokers who stopped smoking at least 3 months prior to screening visit (V1). Subjects must have a smoking history of at least 10 pack-years (20 cigarettes per pack). Pack-years are calculated by multiplying the average packs of cigarettes smoked per day times the number of years.
  • Subjects on stable inhaled corticosteroids are allowed to be enrolled and to remain on the treatment throughout the study.
  • Subjects must be willing to give written informed consent and able to adhere to dose and visit schedules.
  • Subjects must agree to inform their usual treating physician of their participation in this study.
  • Female subjects of childbearing potential must have a negative urine pregnancy test prior to the randomization of the study
  • Nonpregnant women of childbearing potential must be using a medically acceptable, adequate form of birth control.

Exclusion Criteria:

  • Subjects have a current or past history of clinically relevant asthma.
  • Subjects quit smoking less than 3 months prior to the Screening visit (V1).
  • Subjects have required ventilator support for respiratory failure within the last year.
  • Subjects have clinically significant lung disease other than COPD, e.g., bronchiectasis, sarcoidosis, pulmonary fibrosis, tuberculosis, etc.
  • Subjects have undergone lobectomy, pneumonectomy or lung volume reduction surgery.
  • Subjects have had lung cancer diagnosed or treated within the last five years.
  • Subjects require nasal continuous positive airway pressure (CPAP) or bi-level positive airway pressure (Bi-PAP).
  • Subjects have initiated pulmonary rehabilitation within the past 3 months.
  • Subjects use oxygen >= 2 liters per minute for > 2 hours per day.
  • Subjects require chronic or prophylactic treatment with antibiotics.
  • Subjects have significant renal, hepatic, cardiovascular (including cor pulmonale), metabolic, neurologic, hematologic, gastrointestinal, cerebrovascular or other significant medical illness or disorder which, in the judgment of the Investigator, may interfere with the study or require treatment which may affect the evaluation of efficacy and safety of the study drug.
  • Subjects have clinically significant abnormalities on chest x-ray (other than evidence of COPD) at the Screening visit or within the previous year.
  • Women are pregnant or breast-feeding.
  • Subjects cannot adhere to the concomitant medications restrictions and prohibitions.
  • Subjects have used any investigational product within 30 days, or 3 months for any biologic of unknown half-life, prior to the Baseline Visit (V3).
  • Subjects are part of the staff or a family member of the staff personnel directly involved with this study.
  • Subjects have chronic narrow-angle glaucoma.
  • Subjects have symptomatic prostatic hyperplasia or bladder-neck obstruction.
Publications of Results:
Layout table for additonal information
Responsible Party: Merck Sharp & Dohme Corp. Identifier: NCT00139932    
Other Study ID Numbers: P04272
First Posted: August 31, 2005    Key Record Dates
Last Update Posted: March 24, 2017
Last Verified: March 2017
Additional relevant MeSH terms:
Layout table for MeSH terms
Pulmonary Disease, Chronic Obstructive
Lung Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Formoterol Fumarate
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Adrenergic beta-2 Receptor Agonists
Adrenergic beta-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action